Joanna Shields, BenevolentAI CEO
AI tools don't equal guaranteed drug success as BenevolentAI flops dermatitis test
It’s a no for BEN.
BEN-2293, a topical out of London-based BenevolentAI, has failed secondary efficacy measures in a Phase IIa …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
